Cullinan Therapeutics Inc (CGEM)
23.49
+0.70
(+3.07%)
USD |
NASDAQ |
May 31, 16:00
23.50
0.00 (0.00%)
After-Hours: 20:00
Cullinan Therapeutics Enterprise Value: 920.82M for May 31, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 31, 2024 | 920.82M |
| May 30, 2024 | 880.47M |
| May 29, 2024 | 874.13M |
| May 28, 2024 | 894.30M |
| May 24, 2024 | 957.70M |
| May 23, 2024 | 872.40M |
| May 22, 2024 | 900.64M |
| May 21, 2024 | 901.80M |
| May 20, 2024 | 949.06M |
| May 17, 2024 | 902.37M |
| May 16, 2024 | 939.26M |
| May 15, 2024 | 1.107B |
| May 14, 2024 | 1.087B |
| May 13, 2024 | 1.073B |
| May 10, 2024 | 1.098B |
| May 09, 2024 | 1.133B |
| May 08, 2024 | 1.165B |
| May 07, 2024 | 1.256B |
| May 06, 2024 | 1.202B |
| May 03, 2024 | 1.199B |
| May 02, 2024 | 1.154B |
| May 01, 2024 | 1.184B |
| April 30, 2024 | 1.122B |
| April 29, 2024 | 1.128B |
| April 26, 2024 | 1.021B |
| Date | Value |
|---|---|
| April 25, 2024 | 673.61M |
| April 24, 2024 | 652.91M |
| April 23, 2024 | 525.29M |
| April 22, 2024 | 465.51M |
| April 19, 2024 | 467.23M |
| April 18, 2024 | 605.20M |
| April 17, 2024 | 337.00M |
| April 16, 2024 | 312.89M |
| April 15, 2024 | 279.72M |
| April 12, 2024 | 284.89M |
| April 11, 2024 | 315.04M |
| April 10, 2024 | 301.69M |
| April 09, 2024 | 300.40M |
| April 08, 2024 | 299.10M |
| April 05, 2024 | 299.97M |
| April 04, 2024 | 285.32M |
| April 03, 2024 | 307.72M |
| April 02, 2024 | 298.67M |
| April 01, 2024 | 327.10M |
| March 28, 2024 | 266.96M |
| March 27, 2024 | 296.68M |
| March 26, 2024 | 255.77M |
| March 25, 2024 | 262.23M |
| March 22, 2024 | 247.15M |
| March 21, 2024 | 236.82M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-131.04M
Minimum
Dec 27 2022
2.116B
Maximum
Mar 10 2021
352.29M
Average
183.44M
Median
Enterprise Value Benchmarks
| Amgen Inc | 218.38B |
| Gilead Sciences Inc | 100.46B |
| Bristol-Myers Squibb Co | 129.36B |
| Alnylam Pharmaceuticals Inc | 17.43B |
| Arrowhead Pharmaceuticals Inc | 2.339B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -37.15M |
| Total Expenses (Quarterly) | 42.99M |
| EPS Diluted (Quarterly) | -0.86 |
| Earnings Yield | -13.32% |